Skip to main content

Table 2 MLH1–93 single nucleotide polymorphism genotypes in controls, sessile serrated adenomas with dysplasia, traditional serrated adenomas and BRAF mutant cancers

From: MLH1–93 G/a polymorphism is associated with MLH1 promoter methylation and protein loss in dysplastic sessile serrated adenomas with BRAFV600E mutation

  Mismatch Repair Status Total n GG n (%) P-Value* GA n (%) P-Value* AA n (%) P-Value*
Controls   147 87 (59%)   53 (36%)   7 (5%)  
SSAD Deficient 94 44 (47%) 0.036 37 (39%) 0.393 13 (14%) 0.037
  Proficient 30 21 (70%) 9 (30%) 0
TSA Deficient 1 0   1   0  
  Proficient 127 76 (60%)   45 (35%)   6 (5%)  
Cancer Deficient 116 52 (44.8%) 0.011 51 (43.9%) 0.194 13 (11.2%) 0.015
  Proficient 87 55 (63.2%) 30 (34.5%) 2 (2.3%)
  1. *Fisher’s Exact test, significant P-values in italics